DE69912441D1 - Injizierbare wässerige propofoldispersionen - Google Patents

Injizierbare wässerige propofoldispersionen

Info

Publication number
DE69912441D1
DE69912441D1 DE69912441T DE69912441T DE69912441D1 DE 69912441 D1 DE69912441 D1 DE 69912441D1 DE 69912441 T DE69912441 T DE 69912441T DE 69912441 T DE69912441 T DE 69912441T DE 69912441 D1 DE69912441 D1 DE 69912441D1
Authority
DE
Germany
Prior art keywords
propofol
dispersions
injectable aqueous
water
aqueous propofol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69912441T
Other languages
English (en)
Other versions
DE69912441T2 (de
Inventor
Awadhesh K Mishra
Gary W Pace
G Vachon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Skyepharma Canada Inc
Original Assignee
Skyepharma Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Skyepharma Canada Inc filed Critical Skyepharma Canada Inc
Application granted granted Critical
Publication of DE69912441D1 publication Critical patent/DE69912441D1/de
Publication of DE69912441T2 publication Critical patent/DE69912441T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
DE69912441T 1998-08-19 1999-08-18 Injizierbare wässerige propofoldispersionen Expired - Lifetime DE69912441T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9707198P 1998-08-19 1998-08-19
US97071P 1998-08-19
PCT/US1999/018801 WO2000010531A1 (en) 1998-08-19 1999-08-18 Injectable aqueous dispersions of propofol

Publications (2)

Publication Number Publication Date
DE69912441D1 true DE69912441D1 (de) 2003-12-04
DE69912441T2 DE69912441T2 (de) 2004-08-19

Family

ID=22260807

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69912441T Expired - Lifetime DE69912441T2 (de) 1998-08-19 1999-08-18 Injizierbare wässerige propofoldispersionen

Country Status (15)

Country Link
US (2) US7097849B2 (de)
EP (1) EP1105096B1 (de)
JP (1) JP4198318B2 (de)
KR (1) KR100777647B1 (de)
CN (1) CN1221249C (de)
AT (1) ATE252889T1 (de)
AU (1) AU759641B2 (de)
CA (1) CA2338703C (de)
DE (1) DE69912441T2 (de)
DK (1) DK1105096T3 (de)
ES (1) ES2211151T3 (de)
HK (1) HK1040195B (de)
IL (2) IL141095A0 (de)
SE (1) SE0100254L (de)
WO (1) WO2000010531A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100302A (en) * 1999-04-05 2000-08-08 Baxter International Inc. Propofol formulation with enhanced microbial characteristics
KR100801588B1 (ko) * 1999-09-21 2008-02-05 스키에파마 캐나다 인코포레이티드 생물학적 유효 물질의 표면 변형된 미립자 조성물
AU2006201100B2 (en) * 1999-09-21 2009-09-24 Jagotec Ag Surface modified particulate compositions of biologically active substances
GB2359747B (en) 2000-02-29 2002-04-24 Maelor Pharmaceuticals Ltd Anaesthetic formulations
GB0012597D0 (en) * 2000-05-25 2000-07-12 Astrazeneca Ab Formulation
AU6689601A (en) * 2000-06-16 2002-01-02 Rtp Pharma Inc Improved injectable dispersions of propofol
US6399087B1 (en) * 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
IL164217A0 (en) * 2002-04-08 2005-12-18 Guilford Pharm Inc Pharmaceutical compositions containing water-soluble propofol and methods of administering same
WO2004010941A2 (en) * 2002-07-29 2004-02-05 Transform Pharmaceuticals, Inc. Aqueous 2,6-diisopropylphenol pharmaceutical compositions
US7550155B2 (en) * 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
JP2006504771A (ja) * 2002-10-29 2006-02-09 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド システインを伴うプロポフォール
EP1556022A4 (de) * 2002-10-29 2010-03-10 Transform Pharmaceuticals Inc WûSSRIGE PHARMAZEUTISCHE 2,6-DIISOPROPYLPHENOL-ZUSAMMENSETZUNGEN
CA2508441A1 (en) * 2002-12-06 2004-06-24 Otsuka Pharmaceutical Factory, Inc. Propofol-containing fat emulsions
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US8476010B2 (en) 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
EP3527202A1 (de) * 2005-08-31 2019-08-21 Abraxis BioScience, LLC Zusammensetzungen und verfahren zur herstellung schwer wasserlöslicher arzneimittel mit erhöhter stabilität
US7771751B2 (en) * 2005-08-31 2010-08-10 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
US8779004B2 (en) 2006-04-20 2014-07-15 Amgen, Inc. Stable emulsion formulations
EP2244720A4 (de) 2008-01-11 2013-01-16 Us Gov Health & Human Serv Polypeptidimpfstoff und impfstoffstrategie gegen mycobacterium
WO2010082092A1 (en) * 2009-01-13 2010-07-22 Claris Lifesciences Limited Propofol based anesthetic with preservative
CA2770304C (en) 2009-08-04 2019-11-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Anti-rsv immunogens and methods of immunization
US9102742B2 (en) 2010-02-10 2015-08-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention Serologic correlates of protection against Bacillus anthracis infection
WO2011100408A2 (en) 2010-02-10 2011-08-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services, Centers For Disease Control And Prevention Serologic correlates of protection against bacillis anthracis infection
CA2788060C (en) 2010-03-17 2017-07-11 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
JP5591603B2 (ja) * 2010-05-21 2014-09-17 富士フイルム株式会社 プロポフォール含有水中油型エマルション組成物
JP2012012331A (ja) * 2010-06-30 2012-01-19 Fujifilm Corp プロポフォール含有水中油型エマルション組成物
EP2444063A1 (de) 2010-10-20 2012-04-25 Novaliq GmbH Flüssige pharmazeutische Zusammensetzungen zur Abgabe von Wirkstoffen
EP2462921A1 (de) 2010-11-11 2012-06-13 Novaliq GmbH Flüssige pharmazeutische Zusammensetzungen zur Behandlung einer Erkrankung der Hinterseite des Auges
AU2012204932B2 (en) * 2011-01-04 2017-02-23 Novaliq Gmbh O/w-emulsions comprising semifluorinated alkanes
AU2012212591A1 (en) 2011-02-02 2013-07-25 Nestec S.A. High protein nutritional compositions and methods of making and using same
CN107397718A (zh) 2011-05-25 2017-11-28 诺瓦利克有限责任公司 基于半氟化烷烃类的外用药物组合物
EP3181119B1 (de) 2012-09-12 2019-07-10 Novaliq GmbH Zusammensetzungen semifluorierter alkane zur verwendung in der behandlung von keratoconjunctivitis sicca
US9322558B2 (en) * 2013-06-27 2016-04-26 Siemens Aktiengesellschaft Combustor apparatus in a gas turbine engine
EP3331567B1 (de) 2015-07-24 2020-09-23 Neon Laboratories Ltd. Stabilisierte injizierbare emulsion von propofol und ketamin
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
WO2017055454A1 (en) 2015-09-30 2017-04-06 Novaliq Gmbh Semifluorinated compounds and their compositions
ES2803248T3 (es) 2015-09-30 2021-01-25 Novaliq Gmbh 2-perfluorohexil octano para administración oftálmica
PL3442480T3 (pl) 2016-06-23 2020-04-30 Novaliq Gmbh Sposób podawania miejscowego
MX2019003363A (es) 2016-09-22 2019-10-02 Novaliq Gmbh Composiciones farmaceuticas para usarse en la terapia de la blefaritis.
EP3515467B1 (de) 2016-09-23 2023-11-29 Novaliq GmbH Ophthalmische zusammensetzungen mit ciclosporin
AU2018253944B2 (en) 2017-04-21 2022-09-15 Dermaliq Therapeutics, Inc. Iodine compositions
US10717691B2 (en) 2017-05-05 2020-07-21 Novaliq Gmbh Process for the production of semifluorinated alkanes
WO2018206656A1 (en) 2017-05-12 2018-11-15 Novaliq Gmbh Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
CN111372566A (zh) 2017-09-27 2020-07-03 诺瓦利克有限责任公司 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
MX2020009132A (es) 2018-03-02 2020-12-11 Novaliq Gmbh Composiciones farmaceuticas que comprenden nebivolol.
AU2019358249B2 (en) 2018-10-12 2024-02-22 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US11198831B2 (en) 2019-01-31 2021-12-14 Kvi Llc Lubricant for a device
CN110243731B (zh) * 2019-07-03 2021-09-24 苏州新实医疗科技有限公司 抑菌圈直径动态测量方法、测量装置及可读存储介质
WO2023159295A1 (en) * 2022-02-22 2023-08-31 Deciem Beauty Group Inc. Stable, low viscosity oil-in-water emulsions for skin conditioning

Family Cites Families (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2803582A (en) 1956-07-16 1957-08-20 Leonid S Cherney Local anesthetic composition
NL241476A (de) 1958-07-24
US3137631A (en) 1959-12-01 1964-06-16 Faberge Inc Encapsulation in natural products
US3216897A (en) 1961-11-02 1965-11-09 Air Reduction Injectable anesthetic
US3440318A (en) 1964-02-12 1969-04-22 Herbert S Polin Methods for enhancing the effectiveness of drugs,which employ an alkylated phenoxy (polyethanol)
DE1792410B2 (de) 1967-09-01 1980-03-13 Apoteksvarucentralen Vitrum Apotekareaktiebolaget, Stockholm Arzneimittelzubereitung zur intravenösen Injektion
US3594476A (en) 1969-05-12 1971-07-20 Massachusetts Inst Technology Submicron aqueous aerosols containing lecithin
US3937668A (en) 1970-07-15 1976-02-10 Ilse Zolle Method for incorporating substances into protein microspheres
NL7012832A (de) 1970-08-29 1972-03-02
US3715432A (en) 1971-01-22 1973-02-06 Massachusetts Inst Technology Submicron aqueous aerosols containing lecithin
US3885027A (en) * 1971-04-12 1975-05-20 West Laboratories Inc Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US3776857A (en) 1971-09-24 1973-12-04 Witco Chemical Corp Water-in-oil emulsions
US4013100A (en) * 1972-12-08 1977-03-22 Institut Francais Du Petrole, Des Carburants Et Lubrifiants Et Entreprise De Recherches Et D'activities Petrolieres Elf Flexible elongated member comprising a reinforcing armouring
US3794476A (en) 1972-12-26 1974-02-26 Ppg Industries Inc Method for thermally tempering glass sheet by liquid quenching
GB1413186A (en) 1973-06-27 1975-11-12 Toyo Jozo Kk Process for encapsulation of medicaments
GB1472793A (en) 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
US4798846A (en) 1974-03-28 1989-01-17 Imperial Chemical Industries Plc Pharmaceutical compositions
US3965255A (en) 1974-05-01 1976-06-22 E. E. Eljim Ecology Ltd. Controlled drug releasing preparations
GB1502774A (en) 1974-06-25 1978-03-01 Nat Res Dev Immunological preparations
CH588887A5 (de) 1974-07-19 1977-06-15 Battelle Memorial Institute
US4073943A (en) 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
JPS5186117A (en) 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
JPS5231981A (en) 1975-08-18 1977-03-10 Takeda Chem Ind Ltd Microcapsule preparation method
CA1077842A (en) 1975-10-09 1980-05-20 Minnesota Mining And Manufacturing Company Albumin medicament carrier system
US4168308A (en) 1976-03-12 1979-09-18 Apoteksvarucentralen Vitrum Ab Composition for enhancing the administration of pharmacologically active agents
GB1523965A (en) 1976-03-19 1978-09-06 Ici Ltd Pharmaceutical compositions containing steroids
GB1578776A (en) 1976-06-10 1980-11-12 Univ Illinois Hemoglobin liposome and method of making the same
US4078052A (en) 1976-06-30 1978-03-07 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Large unilamellar vesicles (LUV) and method of preparing same
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
US4320121A (en) 1976-10-12 1982-03-16 Sears Barry D Method of emulsifying cholesterol, cholesterol esters and triglyceride compounds
US4351831A (en) 1977-11-02 1982-09-28 Massachusetts Institute Of Technology Process and composition for treating disorders by administering isoxsurpine and choline
US4356167A (en) 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4529561A (en) 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4298594A (en) 1978-04-14 1981-11-03 Arthur D. Little, Inc. Xenobiotic delivery vehicles, method of forming them and method of using them
GB2026340B (en) 1978-07-03 1982-12-22 Ash P Stabilising microvesicles
US4329332A (en) 1978-07-19 1982-05-11 Patrick Couvreur Biodegradable submicroscopic particles containing a biologically active substance and compositions containing them
US4219548A (en) 1978-09-01 1980-08-26 The Procter & Gamble Company Topical anti-inflammatory composition
DE2856333C2 (de) 1978-12-27 1983-09-22 A. Nattermann & Cie GmbH, 5000 Köln Oral einnehmbare Arzneimittel mit entzündungshemmender Wirkung
US4369182A (en) 1978-09-27 1983-01-18 A. Nattermann & Cie Gmbh Inflammation-preventing pharmaceutical composition of oral administration
IT1111367B (it) 1978-11-17 1986-01-13 Serono Ist Farm Processo per la preparazione estemporanea di liposomi e liposomi cosi' ottenuti
GR73668B (de) 1978-11-21 1984-03-28 Hoffmann La Roche
US4328222A (en) 1978-11-21 1982-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions for parenteral or local administration
US4241046A (en) 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4378354A (en) 1978-12-27 1983-03-29 A. Nattermann & Cie. Gmbh Inflammation-preventing pharmaceutical composition of oral administration
US4421747A (en) 1978-12-27 1983-12-20 A. Nattermann & Cie. Gmbh Inflammation-preventing pharmaceutical composition of oral administration
US4316884A (en) 1979-01-25 1982-02-23 Adria Laboratories, Inc. Sustained release pharmaceutical formulation
DE2914788A1 (de) 1979-04-11 1980-10-16 Nattermann A & Cie Parenteral applizierbare, stabile arzneimittelloesungen mit entzuendungshemmender wirkung
US4345588A (en) 1979-04-23 1982-08-24 Northwestern University Method of delivering a therapeutic agent to a target capillary bed
JPS6030652B2 (ja) 1979-05-07 1985-07-17 株式会社ミドリ十字 静脈注射用脂肪乳剤
JPS562353A (en) 1979-06-20 1981-01-12 Ricoh Co Ltd Novel disazo compound and its preparation
CA1173360A (en) 1979-06-22 1984-08-28 Jurg Schrank Pharmaceutical preparations
AR220263A1 (es) 1980-02-19 1980-10-15 Bago Lab Sa Procedimiento para obtener una preparacion inyectable de sulfonamida potenciada de baja irritabilidad
US4302459A (en) 1980-03-19 1981-11-24 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in leishmaniasis chemotherapy with 8-aminoquinoline derivatives
JPS56152739A (en) 1980-04-25 1981-11-26 Tanabe Seiyaku Co Ltd Production of microcapsule
JPS609726B2 (ja) 1980-05-15 1985-03-12 株式会社 ミドリ十字 ステロイド製剤
US4331654A (en) 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
DE3024416C2 (de) 1980-06-28 1982-04-15 Gödecke AG, 1000 Berlin Verfahren zur Herstellung von Arzneimitteln mit retardierter Wirkstoff-Freisetzung
US4394372A (en) 1980-12-22 1983-07-19 The Procter & Gamble Company Process for making lipid membrane structures
US4397372A (en) 1981-03-09 1983-08-09 Bell & Howell Company Pendulum suspended bumper assembly
US4397846A (en) 1981-05-15 1983-08-09 Murray Weiner Storage-stable lipid vesicles and method of preparation
US4394182A (en) 1981-10-14 1983-07-19 Rockwell International Corporation Microelectronic shadow masking process for reducing punchthrough
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
JPS59111636A (ja) 1982-12-17 1984-06-27 Fuji Photo Film Co Ltd 熱現像カラー感光材料およびそれを用いたカラー画像形成方法
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4515736A (en) 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
US4474753A (en) 1983-05-16 1984-10-02 Merck & Co., Inc. Topical drug delivery system utilizing thermosetting gels
US4622219A (en) 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
JPS601122A (ja) 1983-06-20 1985-01-07 Green Cross Corp:The ビフエニリルプロピオン酸誘導体脂肪乳剤
DE3339236A1 (de) 1983-10-28 1985-05-09 Bayer Ag Arzneimittelzubereitung
US4492720A (en) 1983-11-15 1985-01-08 Benjamin Mosier Method of preparing microspheres for intravascular delivery
US4532089A (en) 1984-01-14 1985-07-30 Northwestern University Method of preparing giant size liposomes
DE3406497A1 (de) 1984-02-23 1985-09-05 Mueller Bernhard Willi Werner Hochdisperse pharmazeutische mehrkomponentensysteme und verfahren zu ihrer herstellung
US4610868A (en) 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
JPS60208910A (ja) 1984-03-31 1985-10-21 Green Cross Corp:The 水難溶性薬物・リン脂質複合体の製造方法
FR2562421B1 (fr) 1984-04-09 1989-02-17 Sandoz Sa Perfectionnements a la therapie par l'interleukine
US5288498A (en) * 1985-05-01 1994-02-22 University Of Utah Research Foundation Compositions of oral nondissolvable matrixes for transmucosal administration of medicaments
US4863737A (en) 1985-05-01 1989-09-05 University Of Utah Compositions and methods of manufacture of compressed powder medicaments
US5855908A (en) * 1984-05-01 1999-01-05 University Of Utah Research Foundation Non-dissolvable drug-containing dosage-forms for use in the transmucosal delivery of a drug to a patient
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4761228A (en) 1984-06-08 1988-08-02 Weisenbarger Gale M Magnetic fluid conditioner
JPS6176414A (ja) 1984-09-21 1986-04-18 Shionogi & Co Ltd リポソーム製剤の製法
JPS61174940A (ja) 1985-01-29 1986-08-06 Oogawara Kakoki Kk ワックス類コーテイング単核状マイクロカプセルおよびその製造方法
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
JPH0688911B2 (ja) 1985-06-06 1994-11-09 国立予防衛生研究所長 インフルエンザワクチン及びその製造方法
US4766046A (en) 1985-09-27 1988-08-23 Liposome Technology, Inc. Stabilized liposome/amphotericin composition and method
JPH0617309B2 (ja) 1985-11-29 1994-03-09 株式会社ビタミン研究所 アドリアマイシン包埋リポソ−ム製剤
US4803070A (en) 1986-04-15 1989-02-07 Ribi Immunochem Research Inc. Immunological emulsion adjuvants for polysaccharide vaccines
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4806350A (en) 1986-04-18 1989-02-21 Norden Laboratories, Inc. Vaccine formulation
DE3623376A1 (de) 1986-07-11 1988-01-21 Behringwerke Ag Pharmazeutische formulierung und verfahren zu deren herstellung
FR2602423B1 (fr) 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
US4776991A (en) 1986-08-29 1988-10-11 The United States Of America As Represented By The Secretary Of The Navy Scaled-up production of liposome-encapsulated hemoglobin
US5179079A (en) * 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4839111A (en) 1987-02-02 1989-06-13 The University Of Tennessee Research Corporation Preparation of solid core liposomes
KR880012221A (ko) * 1987-04-13 1988-11-26 사노 가즈오 에스테르 또는 아미드를 활성성분으로 함유하는 약제 조성물
US4798860A (en) 1987-08-21 1989-01-17 Akzo America Inc. Flame resistant organic substances containing polymeric flame retardants
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4937078A (en) 1988-08-26 1990-06-26 Mezei Associates Limited Liposomal local anesthetic and analgesic products
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
IL95952A0 (en) * 1989-10-19 1991-07-18 Sterling Drug Inc Aerosol composition for topical medicament
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
JP2785981B2 (ja) * 1989-11-20 1998-08-13 株式会社資生堂 乳化組成物
US5294604A (en) * 1989-12-20 1994-03-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating ocular diseases by periocular administration of cyclosporine A or G
US5733572A (en) * 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
US5389377A (en) * 1989-12-22 1995-02-14 Molecular Bioquest, Inc. Solid care therapeutic compositions and methods for making same
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
US5091187A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
DE4015108A1 (de) * 1990-05-11 1991-11-14 Leopold Pharma Gmbh Stabile emulsion zur applikation pharmakologisch aktiver wirkstoffe
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5498420A (en) * 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
EP0656779B1 (de) * 1992-08-28 2000-04-12 Pharmos Corporation Emulsionen im submikron-bereich als vehikel zur arzneistoffverabreichung am auge
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
JP3746293B2 (ja) * 1993-02-22 2006-02-15 アメリカン バイオサイエンス、インコーポレイテッド 生物製剤のインビボ送達の方法とそのための組成物
US6190894B1 (en) * 1993-03-19 2001-02-20 The Regents Of The University Of California Method and compositions for disrupting the epithelial barrier function
EP0748215B1 (de) * 1994-02-17 2003-05-28 New York Blood Center, Inc. Biologische bioadhäsive präparate, die fibrinkleber und liposomen enthalten, verfahren für ihre herstellung und verwendung
US5731355A (en) * 1994-03-22 1998-03-24 Zeneca Limited Pharmaceutical compositions of propofol and edetate
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
US5603951A (en) * 1994-11-09 1997-02-18 Hanmi Pharm. Ind. Co., Ltd. Cyclosporin-containing soft capsule compositions
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5589177A (en) * 1994-12-06 1996-12-31 Helene Curtis, Inc. Rinse-off water-in-oil-in-water compositions
GB9426104D0 (en) * 1994-12-23 1995-02-22 Merck Sharp & Dohme Use of surfactants and emulsions
US5885172A (en) * 1997-05-27 1999-03-23 Acushnet Company Multilayer golf ball with a thin thermoset outer layer
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
US6282712B1 (en) * 1995-03-10 2001-08-28 Microsoft Corporation Automatic software installation on heterogeneous networked computer systems
US5496537A (en) * 1995-03-23 1996-03-05 Henry; Richard A. Propofol hydrofluorocarbon propellant formulations
US5882676A (en) * 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
GB9514878D0 (en) * 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
US5705039A (en) * 1995-10-13 1998-01-06 Albemarle Corporation Process for purifying a 2,6-dialkylphenol
US5591311A (en) * 1995-10-26 1997-01-07 Albemarle Corporation Process for purifying a 2,6-dialkylphenol
US5858401A (en) * 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US5637625A (en) * 1996-03-19 1997-06-10 Research Triangle Pharmaceuticals Ltd. Propofol microdroplet formulations
SE9601421D0 (sv) * 1996-04-12 1996-04-12 Astra Ab New composition
US5804585A (en) * 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
US6019997A (en) * 1997-01-09 2000-02-01 Minnesota Mining And Manufacturing Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents
US5990176A (en) * 1997-01-27 1999-11-23 Abbott Laboratories Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
DE19709704C2 (de) * 1997-03-10 1999-11-04 Michael Georgieff Verwendung einer flüssigen Präparation von Xenon zur intravenösen Verabreichung bei Einleitung und/oder Aufrechterhaltung der Anaesthesie
US6090800A (en) * 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US5885597A (en) * 1997-10-01 1999-03-23 Medical Research Industries,Inc. Topical composition for the relief of pain
US6013665A (en) * 1997-12-16 2000-01-11 Abbott Laboratories Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides
DE69937558T2 (de) * 1998-06-03 2008-03-06 Scott Laboratories, Inc., Lubbock Gerät zur linderung von schmerz bei bewusstsein und angstzuständen im zusammenhang mit medizinischen und chirurgischen eingriffen
US6204257B1 (en) * 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
US6025362A (en) * 1998-08-31 2000-02-15 Fukunaga; Atsuo F. Uses of xanthine compounds
US6028108A (en) * 1998-10-22 2000-02-22 America Home Products Corporation Propofol composition comprising pentetate
US6180136B1 (en) * 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
FR2787322B1 (fr) * 1998-12-18 2002-10-18 Galderma Res & Dev Emulsion huile-dans-eau comprenant un agent actif micronise et un systeme emulsionnant approprie
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6177477B1 (en) * 1999-03-24 2001-01-23 American Home Products Corporation Propofol formulation containing TRIS
US6011067A (en) * 1999-06-11 2000-01-04 Thione International, Inc. Antioxidant composition for the treatment of psoriasis and related diseases
US6350480B1 (en) * 1999-12-30 2002-02-26 Wm. Wrigley Jr. Company Chewing gum product including a hydrophilic gum base and method of producing
WO2001085345A1 (en) * 2000-05-10 2001-11-15 Rtp Pharma Inc. Media milling
SE0001865D0 (sv) * 2000-05-19 2000-05-19 Astrazeneca Ab Management of septic shock
US6938619B1 (en) * 2000-06-13 2005-09-06 Scott Laboratories, Inc. Mask free delivery of oxygen and ventilatory monitoring
AU6689601A (en) * 2000-06-16 2002-01-02 Rtp Pharma Inc Improved injectable dispersions of propofol
US6362234B1 (en) * 2000-08-15 2002-03-26 Vyrex Corporation Water-soluble prodrugs of propofol for treatment of migrane
US6552064B2 (en) * 2000-09-19 2003-04-22 University Of Iowa Research Foundation Use of melatonin for induction of general anesthesia

Also Published As

Publication number Publication date
EP1105096B1 (de) 2003-10-29
JP2002523356A (ja) 2002-07-30
AU5570599A (en) 2000-03-14
US20030165544A1 (en) 2003-09-04
ES2211151T3 (es) 2004-07-01
KR100777647B1 (ko) 2007-11-19
ATE252889T1 (de) 2003-11-15
SE0100254L (sv) 2001-04-04
JP4198318B2 (ja) 2008-12-17
SE0100254D0 (sv) 2001-01-30
CN1221249C (zh) 2005-10-05
HK1040195A1 (en) 2002-05-31
CA2338703C (en) 2009-03-24
EP1105096A1 (de) 2001-06-13
US20020006442A1 (en) 2002-01-17
IL141095A (en) 2008-04-13
KR20010099624A (ko) 2001-11-09
CA2338703A1 (en) 2000-03-02
DK1105096T3 (da) 2004-03-08
IL141095A0 (en) 2002-02-10
CN1313758A (zh) 2001-09-19
DE69912441T2 (de) 2004-08-19
HK1040195B (zh) 2006-06-02
AU759641B2 (en) 2003-04-17
WO2000010531A1 (en) 2000-03-02
US7097849B2 (en) 2006-08-29
US7041705B2 (en) 2006-05-09

Similar Documents

Publication Publication Date Title
ATE252889T1 (de) Injizierbare wässerige propofoldispersionen
NO942155D0 (no) Legemiddelformuleringer for parenteral anvendelse
JP2015038216A (ja) 圧縮ガスエアロゾルとして投与するのに適した溶媒和活性剤を含有する組成物
JP2003183157A (ja) 眼科用組成物
HU198123B (en) Deodorant and antibacterial cosmetic
ATE537812T1 (de) Zusammensetzungen und verfahren zur verbesserten verabreichung hydrophober therapeutischer wirkstoffe
DE69418468T2 (de) Viskoelastische zusammensetzungen aus organischen fluorierten verbindungen
US20170105417A1 (en) Skin disinfectant composition and methods for using
KR100260061B1 (en) Vitamin e drop
BR9814296A (pt) Formulação inseticida de aplicação local
US6379688B2 (en) Preservative for emulsion and emulsion containing same
JP2002506820A (ja) 局所用防腐組成物および方法
WO2001070270A3 (en) Base compositions for preparing surfactant free topical compositions
JP4098093B2 (ja) エアゾール製品
JPH08133911A (ja) 抗菌組成物
KR100332615B1 (ko) 구강용겔조성물
KR930001903A (ko) 유비데카레논 경구용 수용액 제제
JP4801300B2 (ja) 外用液状組成物
CA2141703C (en) Mouthwash
JP2004203824A (ja) 鼻腔用組成物及びその使用方法
PT862433E (pt) Composicao farmaceutica espumante topica para o tratamento de dermatoses induzidas por pityrosporum oval
CA2001568A1 (en) Medicament for treating toxoplasmosis
KR900018051A (ko) 트리아졸 화합물, 이를 함유하는 항진균제 및 이를 사용한 만성 진균증의 예방 및/또는 치료법
WO2002049433A3 (fr) Composition cosmetique repulsive active contre les furcocercaires de schistosomes
JPH0240303A (ja) 便座消毒液

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: MEISSNER, BOLTE & PARTNER GBR, 80538 MUENCHEN